Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man

No abstract is available for this paper.

• Publication year

  1995

• Venue

  International Clinical Psychopharmacology

• Publication date

  1995-09-01

• Fields of study

  Medicine, Chemistry, Psychology

• Identifiers
  DOI 10.1097/00004850-199509000-00011PMID 8866769
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels

  2004cited by this paper
• D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.

  1995cited by this paper
• Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.

  1993cited by this paper
• Low-dose depot medication in schizophrenia.

  1993cited by this paper
• Psychopharmacologic treatment of schizophrenia.

  1993cited by this paper
• Depot neuroleptic therapy: an underutilized treatment option.

  1992cited by this paper
• Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

  1992cited by this paper
• Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.

  1991cited by this paper
• Dosage of haloperidol for schizophrenia.

  1991cited by this paper
• A controlled dose comparison of haloperidol in newly admitted schizophrenic patients.

  1990cited by this paper
• D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.

  1990cited by this paper
• Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis

  1989cited by this paper
• Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients.

  1988cited by this paper
• Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.

  1988cited by this paper
• Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

  1988cited by this paper
• Behavioral toxicity of antipsychotic drugs.

  1987cited by this paper
• In Vivo Assay for Neuroleptic Receptor Binding in the Striatum

  1987cited by this paper
• Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

  1986cited by this paper
• High and very high dosage antipsychotics: a critical review.

  1980cited by this paper
• Antipsychotic drug doses and neuroleptic/dopamine receptors

  1976cited by this paper
• Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

  1976cited by this paper
• Overview: maintenance therapy in psychiatry: I. Schizophrenia.

  1975cited by this paper
• A survey of drug-induced extrapyramidal reactions.

  1961cited by this paper

• Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology

  2020cites this paper
• A review of a recently published guidelines' “strong recommendation” for therapeutic drug monitoring of olanzapine, haloperidol, perphenazine, and fluphenazine

  2019cites this paper
• Antipsychotic treatment and basal ganglia volumes: Exploring the role of receptor occupancy, dosage and remission status.

  2019cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2018cites this paper
• Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data

  2017cites this paper
• Use of carbon-11 labelled tool compounds in support of drug development.

  2017cites this paper
• Fatigue and stress reactivity are differently related to cigarette craving and hormone responses to neurotransmitter related drugs in nicotine deprived smokers

  2017cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2017cites this paper
• Prediction of CNS occupancy of dopamine D2 receptor based on systemic exposure and in vitro experiments.

  2016cites this paper
• Haloperidol 2 mg impairs inhibition but not visuospatial attention

  2016cites this paper
• Nigella sativa Oil Reduces Extrapyramidal Symptoms (EPS)-Like Behavior in Haloperidol-Treated Rats

  2016cites this paper
• Discriminating Depression, Physical and Social Anhedonia by Neurotransmitter Related Challenge Tests

  2016cites this paper
• GABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humans

  2016cites this paper
• Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?

  2015cites this paper
• Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia

  2015cites this paper
• Characterising the neuropsychological profile of psychotic symptoms in Alzheimer's disease and imaging D2/3 receptor occupancy during treatment

  2014cites this paper
• Modulation of the gaba ergic control of dopamine neurotransmission

  2014cites this paper
• PET studies on the mechanism of monoaminergic drugs

  2014cites this paper
• AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.

  2014cites this paper
• Therapeutic drug monitoring of atypical antipsychotic drugs

  2014cites this paper
• Molecular imaging PET and SPECT approaches for improving productivity of antipsychotic drug discovery and development.

  2013cites this paper
• Influence of risperidone on balance control in young healthy individuals

  2012cites this paper
• Injected Haloperidol-Induced Motor Deficits are Potentiated in Rats Drinking Green Tea as a Sole Source of Water: Relationship with Dopamine Metabolism in the Caudate

  2012cites this paper
• In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography

  2012cites this paper
• Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.

  2012cites this paper
• Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia

  2011cites this paper
• Antipsychotic Drugs Rapidly Induce Dopamine Neuron Depolarization Block in a Developmental Rat Model of Schizophrenia

  2011cites this paper
• Green Tea ( Camellia sinensis ) Potentiates Haloperidol – Induced Extrapyramidal Symptoms and Decreases Dopamine Metabolism in the Dorsal Striatum of Rats

  2011cites this paper
• AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011

  2011cites this paper
• Contribution of SPECT Measurements of D2 and 5-HT2A Occupancy to the Clinical Development of the Antipsychotic SB-773812

  2011cites this paper
• TOOLS IN PHARMACOVIGILANCE IN PSYCHIATRY: THERAPEUTIC DRUG MONITORING, PHARMACOGENETIC TESTS AND DRUG-DRUG INTERACTIONS DATABASES

  2011cites this paper
• Pharmacokinetic Modeling and [123I]5-IA-85380 Single Photon Emission Computed Tomography Imaging in Baboons: Optimization of Dosing Regimen for ABT-089

  2011cites this paper
• Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

  2010cites this paper
• Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design.

  2010cites this paper
• D2-Receptor Upregulation is Dependent upon Temporal Course of D2-Occupancy: A Longitudinal [11C]-Raclopride PET Study in Cats

  2009cites this paper
• HALOPERIDOL VERSUS RISPERIDONE: A COMPARISON OF BENEFICIAL EFFECT ON COGNITIVE FUNCTION OF PATIENTS WITH CHRONIC SCHIZOPHRENIA

  2008cites this paper
• Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients

  2008cites this paper
• Not for Sale or Commercial Distribution

  2007cites this paper
• From the Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

  2007cites this paper
• Course of Recovery of Cognitive Impairment in Patients with Schizophrenia: A Randomised Double-blind Study Comparing Sertindole and Haloperidol

  2007cites this paper
• Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable.

  2006cites this paper
• The role of emission tomography in pharmacokinetic and pharmacodynamic studies in clinical psychopharmacology

  2006cites this paper
• Occupancy of dopamine D1, D2 and serotonin2A receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol

  2006cites this paper
• Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance

  2006cites this paper
• From THE DEPARTMENT OF CLINICAL NEUROSCIENCE Karolinska Institutet, Stockholm, Sweden PET STUDIES OF THE SEROTONIN TRANSPORTER IN THE HUMAN BRAIN

  2006cites this paper
• Does clozapine work by blocking spikes and sparing bursts?

  2005cites this paper
• First- and second-generation antipsychotic medication and cognitive processing in schizophrenia

  2005cites this paper
• D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients.

  2005cites this paper
• Les syndromes parkinsoniens médicamenteux

  2004cites this paper
• [Drug-induced parkinson syndromes].

  2004cites this paper
• 123I-β-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia

  2004cites this paper
• Adverse effects of risperidone and haloperidol treatment in schizophrenia.

  2004cites this paper
• Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications

  2003cites this paper
• Imaging Antipsychotic Action at Dopamine Receptors

  2003cites this paper
• Positron emission tomography and brain monoamine neurotransmission -- entries for study of drug interactions.

  2002cites this paper
• Antipsychotic Drug-Induced Muscle Rigidity and D2 Receptor Occupancy in the Basal Ganglia of the Rat

  2002cites this paper
• Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole

  2002cites this paper
• Atypical Antipsychotics: Mechanism of Action

  2002cites this paper
• PET in psychopharmacology.

  2001cites this paper
• An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy.

  2001cites this paper
• Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report

  2001cites this paper
• Antipsychotic drugs, dopamine receptors, and schizophrenia

  2001cites this paper
• Biotransformation of Post-Clozapine Antipsychotics

  2000cites this paper
• Biotransformation of post-clozapine antipsychotics: pharmacological implications.

  2000cites this paper
• Non-equipotent doses partly explain differences among antipsychotics – implications of PET studies

  2000cites this paper
• Raclopride and Chlorpromazine, but not Clozapine, Increase Muscle Rigidity in the Rat: Relationship with D2 Dopamine Receptor Occupancy

  1999cites this paper
• Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia

  1999cites this paper
• Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.

  1999cites this paper
• Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders

  1999cites this paper
• The new-generation antipsychotics - integrating the neuropathology and pharmacology of schizophrenia

  1999cites this paper
• Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.

  1999cites this paper
• Long-Acting Antipsychotic Medication, Restraint and Treatment in the Management of Acute Psychosis

  1999cites this paper
• Psychopharmacological Treatment of Personality Disorders

  1999cites this paper
• Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors

  1998cites this paper
• Decline of dopamine: effects of age and acute neuroleptic challenge.

  1998cites this paper
• Functional Imaging of the Brain in the Evaluation of Drug Response and its Application to the Study of Aging

  1998cites this paper
• A Test of the Predictive Validity of Animal Models of Schizophrenia Based on Phencyclidine and D-Amphetamine

  1998cites this paper
• Implications of brain imaging for the management of schizophrenia

  1998cites this paper
• A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects

  1997cites this paper
• Haloperidol serum concentrations and D2 dopamine receptor occupancy during low‐dose treatment with haloperidol decanoate

  1997cites this paper
• The relevance of serotonergic mechanisms in the treatment of schizophrenia has not been confirmed

  1997cites this paper
• Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs.

  1997cites this paper
• Clozapine occupies high levels of dopamine D2 receptors.

  1997cites this paper
• Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients.

  1996cites this paper